ESCMID Conference on
Reviving Old Antibiotics
Vienna, Austria
22 – 24 October 2014
Welcome Address

Dear Colleagues,

It is a great pleasure to welcome you to the ESCMID Conference on Reviving Old Antibiotics! In the face of increasing antimicrobial resistance and the lack of new agents it has become clear that we need new strategies. One of these must be to revisit old antibiotics to make sure that we are using them correctly and to their full potential as well as to find out if one or several of them can help alleviate the pressure on more recent agents. We find it inspiring to share and discuss our old and new knowledge of these agents with you.

It is our pleasure to host this unique conference in the beautiful city of Vienna. Many of the world’s leading experts and researchers have accepted our invitation to actively participate in the meeting. For each session, invited speakers who are at the forefront of their respective fields will discuss how progress at the bench can be translated into actions in the field and highlight gaps in our knowledge. The last day of the conference is dedicated to an extensive panel discussion with ample opportunity for input from the audience and final recommendations about priority research, how gaps in our knowledge may be filled and what policy changes and which funding actions are needed.

Vienna will provide an inspiring environment for this conference but also for top-class music and culture programmes offered in concert halls, museums, and on stage. The reception in the City Hall will give you the opportunity to enjoy the great cultural heritage of Vienna and a relaxing evening with colleagues and friends.

We wish you a fruitful meeting and a wonderful stay in Vienna.

Ursula Theuretzbacher
Chair, Scientific Programme Committee

Gunnar Kahlmeter
ESCMID Past President

Nora Nedkov
ESCMID Events Manager
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:10</td>
<td>Setting the scene</td>
<td>Chair: M. Akova, U. Theuretzbacher</td>
</tr>
<tr>
<td>08:30 – 08:40</td>
<td>Welcome, introduction, opening of the conference</td>
<td>Murat Akova (Turkey)</td>
</tr>
<tr>
<td>08:40 – 09:10</td>
<td>Reviving old antibiotics – a public health need</td>
<td>Dominique L. Monnet, ECDC</td>
</tr>
<tr>
<td>09:10 – 09:40</td>
<td>Usage of old antibiotics now and in the future</td>
<td>Johan W. Mouton (Netherlands)</td>
</tr>
<tr>
<td>09:40 – 10:10</td>
<td>Ethical dilemmas when using old antibiotics</td>
<td>Leonard Leibovici (Israel)</td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td>Optimisation of therapy – general principles</td>
<td>Chair: A. MacGowan, K. Kaye</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Translational basic research for old antibiotics: what is lacking?</td>
<td>Alasdair MacGowan (United Kingdom)</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Optimisation of dosing regimens, dosing in special populations, duration of therapy</td>
<td>Jason Roberts (Australia)</td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>Optimised usage to prevent emergence of resistance and co-selection processes</td>
<td>Vincent H. Tam (United States)</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
<td>Combination therapy – the solution to all problems?</td>
<td>Keith Kaye (United States)</td>
</tr>
<tr>
<td>13:45 – 15:25</td>
<td>Optimisation of therapy in Gram-negative infections</td>
<td>Chair: R. Nation, F. van Bambeke</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>Temocillin</td>
<td></td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Fosfomycin iv</td>
<td>Matthew E. Falagas (Greece)</td>
</tr>
<tr>
<td>14:15 – 14:30</td>
<td>Fosfomycin trometamol</td>
<td>Angela Huttner (Switzerland)</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>14:45 – 15:00</td>
<td>Anouk E. Muller (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>14:45 – 15:45</td>
<td>Mecillinam</td>
<td>Niels Frimodt-Møller (Denmark)</td>
</tr>
<tr>
<td>15:00 – 15:15</td>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>15:15 – 15:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:45 – 17:10</td>
<td>Optimisation and individualisation of therapy</td>
<td>Chair: N. Frimodt-Møller, A. Huttner</td>
</tr>
<tr>
<td>15:45 – 16:10</td>
<td>Colistin</td>
<td>Roger Nation (Australia)</td>
</tr>
<tr>
<td>16:10 – 16:30</td>
<td>Therapeutic drug monitoring of old antibiotics – colistin</td>
<td>William Couet (France)</td>
</tr>
<tr>
<td>16:30 – 16:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:40 – 17:10</td>
<td>Clinical decision making – strategies for individual patients</td>
<td></td>
</tr>
<tr>
<td>17:10 – 17:30</td>
<td>Summary of the first day</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, 23 October 2014

08:30 – 10:00  **Extending the life of old antibiotics**  
*Chair: I. C. Gyssens, M. Paul*  
08:30 – 09:00  Resistance epidemiology and trends in old antibiotics  
Christian G. Giske (Sweden)  
09:00 – 09:30  Impact of resistance on bacteria and epidemiological implications  
Dan Andersson (Sweden)  
09:30 – 10:00  Stewardship aspects for last resort antibiotics  
Inge C. Gyssens (Netherlands)  

10:30 – 12:00  **Clinical trials**  
*Chair: L. Leibovici, J. Turnidge*  
10:30 – 11:00  How do you “re-develop” an old antibiotic: experience from AIDA  
Ursula Theuretzbacher (Austria)  
11:00 – 11:30  Strength and limitations of industry vs. academic randomised controlled trials  
Pierre-Francois Laterre (Belgium)  
11:30 – 12:00  Observational studies vs. randomised controlled trials  
Mical Paul (Israel)  

13:00 – 15:00  **Breakpoints and susceptibility testing**  
*Chair: J. Mouton, R. Canton*  
13:00 – 13:30  ECOFFs for the early detection of resistance development  
Gunnar Kahlmeter (Sweden)  
13:30 – 14:00  Susceptibility testing issues with old antibiotics  
John D. Turnidge (Australia)  
14:00 – 14:30  Drawbacks of available breakpoints  
Rafael Canton Moreno (Spain)  
14:30 – 15:00  Correlations of clinical outcomes and antimicrobial susceptibility testing result  
Alex Soriano (Spain)  

15:30 – 17:05  **Regulating and communicating new knowledge**  
*Chair: G. Kahlmeter, C. G. Giske*  
15:30 – 15:55  Re-evaluating and revising of existing indications  
Mair Powell (United Kingdom)  
15:55 – 16:20  Keeping up-to-date, regulatory issues: EMA  
Radu Botgros (United Kingdom)  
16:20 – 16:40  Dealing with old drugs – the industry’s perspective  
Holger von Fircks (Sweden)  
16:40 – 17:05  Organising and communicating changes of knowledge to the medical community  
Otto Cars (Sweden)  

17:20 – 17:50  **Late breaker presentations: national and international actions**  
*Chair: O. Cars*  
17:20 – 17:30  MSF: relevance of old antibiotics in developing countries  
Christophe Perrin (Switzerland)  
17:30 – 17:40  WHO  
Charles Penn (Switzerland)  
17:40 – 17:50  Governmental action – example Sweden  
Charlotta Edlund (Sweden)
Scientific Programme

Friday, 24 October 2014

08:30 – 10:30  Round table discussion
Chair: U. Theuretzbacher, G. Kahlmeter

Within preceding sessions key issues will be identified to be discussed among panel members and the audience. Solved and unsolved problems with old antibiotics in the following areas: Preclinical and clinical studies, stewardship, preserving efficacy, breakpoints, regulatory and industry perspectives, bringing new knowledge to the clinician.

10:50 – 12:20  Consensus session
Chair: U. Theuretzbacher, G. Kahlmeter

Discuss and agree on need for action. Input from the audience will be highly appreciated.

12:20 – 12:30  Conclusion and closing of the conference

Faculty Members

Murat Akova (Ankara, Turkey)
Dan Andersson (Uppsala, Sweden)
Radu Botgros (London, United Kingdom)
Rafael Canton Moreno (Madrid, Spain)
Otto Cars (Uppsala, Sweden)
William Couet (Poitiers, France)
George L. Daikos (Athens, Greece)
Charlotta Edlund (Solna, Sweden)
Noa Eliakim (Petah-Tiqva, Israel)
Matthew E. Falagas (Athens, Greece)
Niels Frimodt-Møller (Hvidovre, Denmark)
Christian G. Giske (Stockholm, Sweden)
Inge C. Gyssens (Nijmegen, Netherlands)
Angela Huttner (Geneva, Switzerland)
Gunnar Kahlmeter (Växjö, Sweden)
Keith Kaye (Huntington Woods, United States)
Pierre-Francois Laterre (Louvain-la-Neuve, Belgium)
Leonard Leibovici (Petah-Tiqva, Israel)
Alasdair MacGowan (Bristol, United Kingdom)
Dominique L. Monnet (Stockholm, Sweden)
Johan W. Mouton (Nijmegen, Netherlands)
Anouk E. Muller (Tilburg, Netherlands)
Roger L. Nation (Melbourne, Australia)
Mical Paul (Haifa, Israel)
Charles Penn (Geneva, Switzerland)
Christophe Perrin (Geneva, Switzerland)
Mair Powell (London, United Kingdom)
Jason Roberts (Brisbane, Australia)
Alex Soriano (Barcelona, Spain)
Vincent H. Tam (Houston, United States)
Ursula Theuretzbacher (Vienna, Austria)
John D. Turnidge (Adelaide, Australia)
Francoise van Bambeke (Brussels, Belgium)
Holger von Fircks (Solna, Sweden)
All accepted abstracts are scheduled for poster presentation on Wednesday, 22 October and Thursday, 23 October 2014. The selection is based on a blind review by at least two experts in each field. The posters are displayed in the poster and coffee break area “Österreich – Ungarn”. The poster area is open to participants during session hours / breaks on 22 – 23 October.

**Poster Presentation P01**

Efficacy of old antibiotics against commonly isolated microorganisms in a tertiary care hospital

*Majumder, S. [India]*

**Poster Presentation P02**

Comparative *in vitro* activity of temocillin and other beta-lactams against *Pseudomonas aeruginosa* isolated from cystic fibrosis patients

*Chalhoub, H. [Belgium]*

**Poster Presentation P03**

*In vitro* activity of fosfomycin and tigecycline against carbapenemase-producing Enterobacteriaceae in a tertiary care hospital in Singapore

*Choudhury, S. [Singapore]*

**Poster Presentation P04**

*In vitro* activity of nitroxoline

*Naber, K.G. [Germany]*

**Poster Presentation P05**

Prevalence of multidrug-resistant *Klebsiella pneumoniae* strains producing carbapenemases (MDR-KPC) and increase of resistance to colistin

*Bartolini, A. & Santacatterin, E. [Italy]*

**Poster Presentation P06**

Old drugs for new bugs, the chaotic Lebanese scenario: a developing country’s perspective

*Bizri, A. [Lebanon]*

**Poster Presentation P07**

Resistant strains of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* from intensive care unit

*Yergaliyeva, A. [Kazakhstan]*

**Poster Presentation P08**

Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase (ESBL) and non-ESBL producing enteric Gram-negative bacteria and activity of nitrofurantoin in the era of ESBL

*Fatemi, A. [Iran]*
**Poster Presentation P09**
Influence of antibiotic gentamicin on mitogen-induced tryptophan breakdown *in vitro*
Gostner, J.M. (Austria)

**Poster Presentation P10**
*In vitro* activity of rifaximin combined with colistin or polymyxins B against multidrug-resistant Gram-negative bacteria. A potential combination regimen for selective decontamination of the digestive tract?
Betts, J.W. (United Kingdom)

**Poster Presentation P11**
The investigation of colistin resistance mechanisms in clinical isolates of *Klebsiella pneumoniae*
Kocsis, B. (Hungary)

**Poster Presentation P12**
A deletion in lumazine synthase contributes to nitrofurantoin resistance in *Escherichia coli*
Xavier, B.B. (Belgium)

**Poster Presentation P13**
Resistance of CA-MRSA isolates from healthy population to non-beta-lactam antibiotics in Pomoravlje district
Petrovi Jeremi, L.J. (Serbia)

**Poster Presentation P15**
High macrolide resistant *Moraxella catarrhalis* and development of an allele-specific PCR assay for detection of 23S rRNA gene A2330T mutation: a 3-year study at a Chinese tertiary hospital
Liu, Y.L. (China)

**Poster Presentation P17**
Heteroresistance to colistin in *Klebsiella pneumoniae*
Xavier, B.B. (Belgium)

**Poster Presentation P18**
A novel triple combination of fosfomycin, chloramphenicol and colistin for the treatment of *Pseudomonas aeruginosa* infection
Betts, J.W. (United Kingdom)

**Poster Presentation P19**
Interactions between doxycycline and non-antibiotic drugs used in canine medicine
Maaland, M.G. (Denmark)

**Poster Presentation P20**
Bactericidal activity of ciprofloxacin dry powder for inhalation [DPI] in a hollow fiber [HF] model
Glenschek-Sieberth, M. (Germany)

**Poster Presentation P21**
*Galleria mellonella*: an *in vitro* model for assessing the efficacy of colistin combinations with broad-spectrum antibiotics against biofilm-forming *Acinetobacter baumannii* infections
Gillett, A.R. (United Kingdom)

**Poster Presentation P22**
Novel antivirulence agents sensitize MRSA to beta-lactam antibiotics
Shoham, M. (United States)

**Poster Presentation P23**
Phosphonopeptides revisited, in the era of multidrug-resistant Enterobacteriaceae
Marrs, E.C.L. (United Kingdom)

**Poster Presentation P24**
Method for detecting levels of antibiotics in blood paves the way to individualised treatments
Wafula Ndiefira, J. (United Kingdom)
Poster Presentations

**Poster Presentation P25**
Pharmacokinetics of colistin after the administration of two different loading doses of colistin methanesulfonate (CMS) in critically ill patients
_Pachón-Ibañez, M.E. (Spain)_

**Poster Presentation P26**
Clinical pharmacokinetics of temocillin in patients with end-stage renal disease undergoing haemodialysis
_Miranda Bastos, A.C. (Belgium)_

**Poster Presentation P27**
Difference in clearance of vancomycin by Rac
_Sungmin Kiem (Rep. of Korea)_

**Poster Presentation P28**
Revisiting paediatric penicillin pharmacokinetics: the feasibility of opportunistic sampling strategies
_Barker, C.I. (United Kingdom)_

**Poster Presentation P29**
Risk assessment for amikacin inhale in ICU patients using whole body physiologically based PK-models
_Stass, H. (Germany)_

**Poster Presentation P30**
Lung deposition of ciprofloxacin DPI in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD) or non-cystic fibrosis bronchiectasis (NCFB)
_Stass, H. (Germany)_

**Poster Presentation P31**
Efficacy of ciprofloxacin against resistant _P. aeruginosa_ isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics (PK) after ciprofloxacin DPI treatment
_Glenschek-Sieberth, M. (Germany)_

**Poster Presentation P32**
Inhalatory antibiotic therapy in cystic fibrosis and emergence of colistin-resistant Gram-negative non-fermenting bacteria: a new problem in pulmonary infection treatment?
_Morelli, P (Italy)_

**Poster Presentation P33**
Study of the use of colistin in a large orthopaedic/truma hospital of Greece
_Stefani, D. (Greece)_

**Poster Presentation P34**
Multiple-dose regimen of intravenous and oral fosfomycin tromethamine as a potential therapy for the treatment of systemic infections due to multidrug-resistant bacteria
_Ortiz Zacarías N.V. (Netherlands)_

**Poster Presentation P35**
Nitroxoline for treatment of uncomplicated UTI IPD – meta-analysis for four controlled clinical studies
_Naber, K.G. (Germany)_
Impressions

Vienna

Austria Trend Parkhotel Schönbrunn

General Information

**Networking Evening, 23 October 2014, 19.30**

The Networking Evening will be celebrated in the City Hall of Vienna. Transfer from the conference venue will be organised. More information can be found on the invitation.

Vienna City Hall
Felderstrasse 1
1010 Vienna, Austria
Price: 20 € p.P

**Organising Committee**

Rafael Cantón Moreno (Madrid, Spain)
Christian Giske (Stockholm, Sweden)
Gunnar Kahlmeter (Växjö, Sweden)
Alasdair MacGowan (Bristol, United Kingdom)
Johan Mouton (Nijmegen, Netherlands)
Roger Nation (Melbourne, Australia)
Mical Paul (Tel Aviv, Israel)
Ursula Theuretzbacher (Vienna, Austria)
John Turnidge (Adelaide, Australia)
Françoise van Bambeke (Brussels, Belgium)
**General Information**

**Scientific Secretariat**
- Ursula Theuretzbacher
- Nora Nedkov
ESCMID Executive Office
P.O. Box 214
4010 Basel, Switzerland
Phone +41 61 508 01 52
www.escmid.org/vienna2014

**Conference Secretariat**
- ESCMID Conference 2014
- Helga Eismair
Austropa Interconvention
Verkehrsbuero Kongress Management GmbH
Lassallestrasse 3
1020 Vienna, Austria
ESCMID2014@interconvention.at

**Conference Venue**
- Austria Trend Parkhotel Schönbrunn
Hietzinger Hauptstr. 10 – 14
1130 Vienna, Austria